Literature DB >> 16985043

Mesothelin is shed from tumor cells.

Mitchell Ho, Masanori Onda, Qing-Cheng Wang, Raffit Hassan, Ira Pastan, Mark O Lively.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16985043     DOI： 10.1158/1055-9965.EPI-06-0479

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN： 1055-9965            Impact factor:   4.254


× No keyword cloud information.
  27 in total

1.  A multifunctional mesothelin antibody-tagged microparticle targets human mesotheliomas.

Authors:  Sherrill L Macura; Jedd M Hillegass; Jeremy L Steinbacher; Maximilian B MacPherson; Arti Shukla; Stacie L Beuschel; Timothy N Perkins; Kelly J Butnor; Melissa J Lathrop; Mutlay Sayan; Khan Hekmatyar; Douglas J Taatjes; Risto A Kauppinen; Christopher C Landry; Brooke T Mossman
Journal:  J Histochem Cytochem       Date:  2012-06-21       Impact factor: 2.479

2.  Hunting for a pleural fluid test for mesothelioma: is soluble mesothelin the answer?

Authors:  Y C Gary Lee
Journal:  Thorax       Date:  2007-07       Impact factor: 9.139

Review 3.  Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin.

Authors:  Mitchell Ho
Journal:  BioDrugs       Date:  2011-10-01       Impact factor: 5.807

4.  Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma.

Authors:  Jenette Creaney; Deborah Yeoman; Leanne K Naumoff; Michelle Hof; Amanda Segal; Arthur William Musk; Nicholas De Klerk; Nora Horick; Steven J Skates; Bruce W S Robinson
Journal:  Thorax       Date:  2007-03-13       Impact factor: 9.139

5.  A binding domain on mesothelin for CA125/MUC16.

Authors:  Osamu Kaneko; Lucy Gong; Jingli Zhang; Johanna K Hansen; Raffit Hassan; Byungkook Lee; Mitchell Ho
Journal:  J Biol Chem       Date:  2008-12-15       Impact factor: 5.157

6.  Mesothelin as a potential therapeutic target in human cholangiocarcinoma.

Authors:  Liping Yu; Mingqian Feng; Heungnam Kim; Yen Phung; David E Kleiner; Gregory J Gores; Min Qian; Xin Wei Wang; Mitchell Ho
Journal:  J Cancer       Date:  2010-10-01       Impact factor: 4.207

7.  Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors.

Authors:  Yujian Zhang; Laiman Xiang; Raffit Hassan; Ira Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-16       Impact factor: 11.205

Review 8.  Discovery of mesothelin and exploiting it as a target for immunotherapy.

Authors:  Ira Pastan; Raffit Hassan
Journal:  Cancer Res       Date:  2014-05-13       Impact factor: 12.701

9.  Mesothelin Enhances Tumor Vascularity in Newly Forming Pancreatic Peritoneal Metastases.

Authors:  Leela Rani Avula; Michael Rudloff; Salma El-Behaedi; Danielle Arons; Rakan Albalawy; Xiongfong Chen; Xianyu Zhang; Christine Alewine
Journal:  Mol Cancer Res       Date:  2019-11-01       Impact factor: 5.852

10.  A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake.

Authors:  Yujian Zhang; Johanna K Hansen; Laiman Xiang; Seiji Kawa; Masanori Onda; Mitchell Ho; Raffit Hassan; Ira Pastan
Journal:  Cancer Res       Date:  2010-01-26       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.